



DEFINITIONS



HINTS AND TIPS



FAQs



REGISTER TRIAL



MY TRIALS

## Trial Review

COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

[VIEW TRIAL AT REGISTRATION](#)
[VIEW HISTORY](#)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this [information for consumers](#)

[< BACK](#)

### Trial registered on ANZCTR

<b>Registration number</b>	 ACTRN12619000315112
<b>Ethics application status</b>	 Approved
<b>Date submitted</b>	 26/02/2019
<b>Date registered</b>	 28/02/2019
<b>Date last updated</b>	 8/10/2019
<b>Date data sharing statement initially provided</b>	 28/02/2019
<b>Date results information initially provided</b>	 8/10/2019
<b>Type of registration</b>	 Prospectively registered

#### Titles & IDs

<b>Public title</b>	Assessing hypercoagulability after total hip arthroplasty
<b>Scientific title</b>	A retrospective evaluation of hypercoagulability detected by thromboelastography (TEG) in patients undergoing elective total hip arthroplasty who received a TEG as part of standard care.
<b>Secondary ID [1]</b>	None
<b>Universal Trial Number (UTN)</b>	U1111-1229-2715
<b>Trial acronym</b>	None
<b>Linked study record</b>	Not applicable

#### Health condition

##### Health condition(s) or problem(s) studied:

Orthopaedic surgery

Total hip arthroplasty

##### Condition category

Surgery

Anaesthesiology

Blood

##### Condition code

Other surgery

Anaesthetics

Clotting disorders

#### Intervention/exposure

##### Study type

	Observational
<b>Patient registry</b>	False
<b>Target follow-up duration</b>	
<b>Target follow-up type</b>	
<b>Description of intervention(s) / exposure</b>	This retrospective observational study will include the records of patients who have undergone elective total hip arthroplasty under general and spinal anaesthesia who have had a thromboelastograph done as part of routine clinical care. We aim to review thromboelastograph from the time of surgery until patient discharge. As this is a retrospective audit of the medical records, no patient involvement is required. Patients will not be contacted in any way, and all information extracted from the records will be de-identified and aligned with hospital governance processes for clinical audit and retrospective data collection.
<b>Intervention code [1]</b>	Early Detection / Screening
<b>Comparator / control treatment</b>	For patients who have undergone elective total hip arthroplasty who have had a thromboelastograph done as part of routine care, we will compare the thromboelastograph in patients who have had their surgery performed under general anaesthesia to those who have had their surgery performed under spinal anaesthesia.
<b>Control group</b>	Active

## Outcomes

<b>Primary outcome [1]</b>	The development of a hypercoagulable state as evident by the maximum amplitude (measured in millimeters). This information will be obtained by reviewing the medical records. There is no patient contact at any point.
<i>Timepoint [1]</i>	From the time of surgery to hospital discharge.
<b>Secondary outcome [1]</b>	The development of a hypercoagulable state as evident by the R-time (measured in minutes) on the thromboelastograph. This information will be obtained by reviewing the medical records. There is no patient contact at any point.
<i>Timepoint [1]</i>	From the time of surgery to hospital discharge.
<b>Secondary outcome [2]</b>	The development of a hypercoagulable state as evident by the K-Time (measured in minutes) on the thromboelastograph. This information will be obtained by reviewing the medical records. There is no patient contact at any point.
<i>Timepoint [2]</i>	From the time of surgery to hospital discharge.
<b>Secondary outcome [3]</b>	The development of a hypercoagulable state as evident by the Alpha Angle (measured in degrees) on the thromboelastograph. This information will be obtained by reviewing the medical records. There is no patient contact at any point.
<i>Timepoint [3]</i>	From the time of surgery to hospital discharge.
<b>Secondary outcome [4]</b>	The development of a hypercoagulable state as evident by the clot lysis at 30 minutes on the thromboelastograph. This is measure by the amplitude of the thromboelastograph at this time point. This information will be obtained by reviewing the medical records. There is no patient contact at any point.
<i>Timepoint [4]</i>	From the time of surgery to hospital discharge.

## Eligibility

<b>Key inclusion criteria</b>	Adult patients (age greater 18 years), undergoing elective primary total hip arthroplasty under a general or spinal anaesthetic
<b>Minimum age</b>	18 Years
<b>Maximum age</b>	No limit
<b>Gender</b>	Both males and females
<b>Can healthy volunteers participate?</b>	No
<b>Key exclusion criteria</b>	Emergency hip arthroplasty Patients who have not had a thromboelastogram performed as part of routine clinical care

## Study design

<b>Purpose</b>	Natural history
<b>Duration</b>	Longitudinal
<b>Selection</b>	Defined population
<b>Timing</b>	Retrospective
<b>Statistical methods / analysis</b>	Given that this is a retrospective audit, simple descriptive statistics will be performed. For non-normally distributed data we will use non-parametric statistical analysis (Friedman's test) followed by the Wilcoxon signed rank test with Bonferroni correction to evaluate changes in TEG over time in each group. We will

use the Mann-Whitney U test to compare data between patients having general anaesthesia and patients having spinal anaesthesia at any given sampling time point. Data will be entered as medians with quartiles. A  $p < 0.05$  will be considered statistically significant.

## Recruitment

<b>Recruitment status</b>	Completed		
<b>Date of first participant enrolment</b>			
<b>Anticipated</b>	1/03/2019	<b>Actual</b>	8/04/2019
<b>Date of last participant enrolment</b>			
<b>Anticipated</b>	10/03/2019	<b>Actual</b>	27/05/2019
<b>Date of last data collection</b>			
<b>Anticipated</b>	10/03/2019	<b>Actual</b>	3/06/2019
<b>Sample size</b>			
<b>Target</b>	52	<b>Accrual to date</b>	<b>Final</b> 52
<b>Recruitment in Australia</b>			
<b>Recruitment state(s)</b>	VIC		
<b>Recruitment hospital [1]</b>	Austin Health - Austin Hospital - Heidelberg		
<b>Recruitment hospital [2]</b>	Austin Health - Heidelberg Repatriation Hospital - Heidelberg West		
<b>Recruitment postcode(s) [1]</b>	3084 - Heidelberg		

## Funding & Sponsors

<b>Funding source category [1]</b>	Hospital
<b>Name [1]</b>	Austin Health
<b>Address [1]</b>	145 Studley Road, Heidelberg, 3084, Victoria, Australia
<b>Country [1]</b>	Australia
<b>Primary sponsor type</b>	Hospital
<b>Name</b>	Austin Health
<b>Address</b>	145 Studley Road, Heidelberg, 3084, Victoria, Australia
<b>Country</b>	Australia
<b>Secondary sponsor category [1]</b>	None
<b>Name [1]</b>	
<b>Address [1]</b>	
<b>Country [1]</b>	

## Ethics approval

<b>Ethics application status</b>	Approved
<b>Ethics committee name [1]</b>	Austin Health Research Ethics Committee
<b>Ethics committee address [1]</b>	145 Studley Road, Austin Health, Heidelberg, 3084, Victoria, Australia
<b>Ethics committee country [1]</b>	Australia
<b>Date submitted for ethics approval [1]</b>	25/02/2019
<b>Approval date [1]</b>	05/04/2019
<b>Ethics approval number [1]</b>	LNR/19/Austin/21

## Summary

<b>Brief summary</b>	<p>This retrospective observational study will be conducted by the Department of anaesthesia.</p> <p>Total hip arthroplasty (THA) can result in a significant surgical stress, which in turn can trigger a hypercoagulable state. These patients are at significant risk for the development of thromboembolic complications. Despite venous thromboembolism (VTE) chemoprophylaxis being administered to all patients who undergo THA at Austin Health, VTE remains a common cause of preventable death and a</p>
----------------------	--

well recognised complication after total THA. Despite combining extended VTE chemoprophylaxis with early mobilization, compression stockings and intermittent pneumatic compression devices, many patients at Austin Health who undergo THA remain at high risk for VTE because of advanced age, extensive surgical procedures, and greater medical comorbidities. Furthermore, a large multicenter study showed that most VTE's occur due to prophylaxis failure rather than failure to provide prophylaxis. Although several agents have been shown to reduce the risk of thromboembolic disease, there is no clear preference for thromboembolic chemoprophylaxis for patients undergoing elective total hip arthroplasty.

Thromboelastography (TEG) measures whole blood coagulation and fibrinolysis providing a global view of the interaction between all components of clot formation, retraction and lysis. TEG is one of the most sensitive methods currently available for the assessment of a perioperative hypercoagulable state with numerous reports in surgical patients demonstrating an association between TEG measured variables, anaesthetic techniques, and postoperative thrombotic events. Studies have demonstrated that major joint arthroplasty is associated with activation of coagulation (hypercoagulable state) as measured by TEG, however there have been few comparisons of the effects of general and regional anaesthesia techniques on coagulation.

Therefore, we propose to perform a retrospective audit of patients who underwent THA at Austin Health, who received a TEG as part of routine care.

The primary aims of this retrospective review are to determine if VTE chemoprophylaxis with low molecular weight heparin prevents hypercoagulability after THA (as assessed by TEG) and if general or spinal anaesthesia had similar effects on perioperative coagulability as measured by TEG.

Notably, there will be NO CLINICAL or patient contact at any point. All data collected has already been collected as part of routine clinical care according to standard anaesthesia and surgical processes. No new data will be collected.

<b>Trial website</b>	Not applicable
<b>Trial related presentations / publications</b>	
<b>Public notes</b>	

## Contacts

---

### Principal investigator

<b>Name</b>	A/Prof Laurence Weinberg
<b>Address</b>	Department of Anaesthesia, Austin Health, Studley Road, Heidelberg, Victoria, Australia, 3084
<b>Country</b>	Australia
<b>Phone</b>	+61 394965000
<b>Fax</b>	+61 394966421
<b>Email</b>	laurence.weinberg@austin.org.au

### Contact person for public queries

<b>Name</b>	A/Prof Laurence Weinberg
<b>Address</b>	Department of Anaesthesia, Austin Health, Studley Road, Heidelberg, Victoria, Australia, 3084
<b>Country</b>	Australia
<b>Phone</b>	+61 394965000
<b>Fax</b>	+61 394966421
<b>Email</b>	laurence.weinberg@austin.org.au

### Contact person for scientific queries

<b>Name</b>	A/Prof Laurence Weinberg
<b>Address</b>	Department of Anaesthesia, Austin Health, Studley Road, Heidelberg, Victoria, Australia, 3084
<b>Country</b>	Australia
<b>Phone</b>	+61 394965000
<b>Fax</b>	+61 394966421
<b>Email</b>	laurence.weinberg@austin.org.au

## Data sharing statement

---

<b>Will individual participant data (IPD) for this trial be available (including data dictionaries)?</b>	No
--	----

No/undecided IPD sharing  
reason/comment

This is a retrospective study and a non international study

**What supporting documents  
are/will be available?**

No other documents available

## Summary results

---

**Have study results been  
published in a peer-reviewed  
journal?**

No

Other publications

---

Have study results been made  
publicly available in another  
format?

---

Results – basic reporting

Results – plain English summary

[< BACK](#)

### ANZCTR

Home  
About us  
Statistics  
Useful links  
News  
Contact  
Privacy  
Terms and conditions

### Register a trial

Create account  
Login  
How to register a trial  
How to update a trial  
Data item definitions  
Hints and tips  
FAQs

### Search for a trial

Find a trial  
How to search  
How to get involved

### Major funders



[Privacy](#) | [Disclaimer](#)  
Web design by G Squared

Copyright © Australian New Zealand Clinical Trials Registry. All rights reserved.